^
    over1year
    Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors (AACR 2023)
    In this study, both 225Ac-HER3 ARC and 177Lu-HER3 ARC demonstrated significant antitumor activity against HER3-expressing tumors in a dose-dependent manner. The HER3 targeted radiotherapy approach that we have undertaken could potentially overcome the limitations of current solid tumor therapies in resistance settings and warrants further evaluation in patients with HER3-expressing tumors.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    ERBB3 expression
    |
    Ac-225 ErbB3 targeted radiotherapy • 177Lu-HER3 ARC